Back to Journals » International Journal of Nanomedicine » Volume 13

Development of transmucosal patch loaded with anesthetic and analgesic for dental procedures and in vivo evaluation [Corrigendum]

Authors Nidhi M, Patro M N, Somisetty K, Vemula K

Received 1 December 2017

Accepted for publication 1 December 2017

Published 27 March 2018 Volume 2018:13 Pages 1867—1868

DOI https://doi.org/10.2147/IJN.S158636



Nidhi M, Patro MN, Kusumvalli S, Kusumdevi V. Int J Nanomedicine. 2016;11:2901–2920.

On page 2905, section ‘Transport of LB and DDEA across Caco-2 cell monolayer’, some of the values were incorrectly presented. The corrected text should read:

Prior to transport, the culture medium was replaced by 600 μL of transport medium (Dulbecco’s Modified Eagle’s Medium [DMEM]-F12-buffered with 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid [HEPES]), 10% fetal bovine serum, and antibiotics penstrip (1% v/v), gentamicin (250 μg/mL), and chloramphenicol (23 ng/mL), and cells were allowed to equilibrate for 30 minutes. After the transport medium was discarded, 600 μL of pure drugs LB, DDEA, DDEA-SLN, and TP prepared in dimethyl sulfoxide (10% w/v) suspended in DMEM-F12-HEPES was applied to the apical side, and 600 μL of DMEM-F12-HEPES was added to the basolateral (BL) side. At predetermined time intervals, transepithelial electrical resistance was measured, and 50 μL of the aliquot was withdrawn from the BL side for quantification of the transported drug.

Read the original article


Creative Commons License © 2018 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.